Communiqués ADC Therapeutics SA

Actions

ADCT

CH0499880968

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 18:40:58 16/07/2026			Varia. 5j.	Varia. 1 janv.
1,275 ^USD	-0,39%		-3,08%	-64,31%

30/06	ADC Therapeutics SA achève le recrutement pour l'essai de phase 1b LOTIS-7 évaluant ZYNLONTA en association	CI
30/06	ADC Therapeutics achève le recrutement pour l'étude LOTIS-7 sur le lymphome	MT

Communiqués

01/07	ADC Therapeutics Announces New Employee Inducement Grant	PR
30/06	ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial	PR
24/06	ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities	PR
03/06	ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma	PR
04/05	ADC Therapeutics : (ADCT 1Q 2026 Earnings)	PU
04/05	ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates	PR
01/05	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan	PR
27/04	ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026	PR
01/04	ADC Therapeutics Announces New Employee Inducement Grant	PR
10/03	ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update	PR
03/03	ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026	PR
02/03	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan	PR
24/02	ADC Therapeutics to Participate in March Investor Conferences	PR
23/02	ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement	PR
02/02	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan	PR
30/01	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium	PR
12/01	ADC Therapeutics : (JPMUpdateJan2026 010826)	PU
12/01	ADC Therapeutics : Presentation (JPMUpdateJan2026 010826)	PU
08/01	ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates	PR
08/01	ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference	PR
02/01	ADC Therapeutics Announces New Employee Inducement Grant	PR
19/12	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines	PR
03/12	ADC Therapeutics : (ADCT Webcast Presentation 120225)	PU
03/12	ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	PR
02/12	ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial	PR